The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EDIT | -14.19% | -91.31% | -38.64% | -86% |
| S&P | +12.57% | +87.93% | +13.44% | +252% |
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
The company's CEO made quite the encouraging statement regarding its immediate future.
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.54M | 12265.6% |
| Gross Profit | $6.82M | 543.6% |
| Gross Margin | 90.44% | 2611.8% |
| Market Cap | $312.02M | 10.9% |
| Market Cap / Employee | $1.27M | 0.0% |
| Employees | 246 | -7.2% |
| Net Income | -$25.12M | 59.6% |
| EBITDA | -$23.83M | 62.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $165.65M | 72.9% |
| Accounts Receivable | $8.13M | 6352.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $67.63M | 206.1% |
| Short Term Debt | $11.09M | -32.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -75.51% | -24.9% |
| Return On Invested Capital | -62.44% | -21.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$31.28M | 43.7% |
| Operating Free Cash Flow | -$30.84M | 41.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.60 | 0.71 | 2.95 | 15.80 | 886.14% |
| Price to Sales | 3.25 | 2.69 | 4.77 | 6.74 | 47.98% |
| Price to Tangible Book Value | 0.60 | 0.71 | 2.95 | 15.80 | 886.13% |
| Enterprise Value to EBITDA | 3.94 | 2.80 | -3.60 | -9.47 | 1009.90% |
| Return on Equity | -98.1% | -140.8% | -188.6% | -211.4% | 169.06% |
| Total Debt | $35.03M | $31.13M | $77.81M | $78.72M | 104.53% |
EDIT earnings call for the period ending September 30, 2021.
EDIT earnings call for the period ending June 30, 2021.
EDIT earnings call for the period ending March 31, 2021.
EDIT earnings call for the period ending .
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
